The accumulation of 89Zr-atezolizumab, a PD-L1 antibody, in patients with breast, lung, and bladder cancers showed a higher predictive value than immunohistochemistry or genomic sequencing for therapeutic response (16). This evidence concerns the gene CD274 and urinary bladder carcinoma.